<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34843548</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>07</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>11</Issue><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis: Correlations between fluid biomarkers of NfL, TDP-43, and tau, and clinical characteristics.</ArticleTitle><Pagination><StartPage>e0260323</StartPage><MedlinePgn>e0260323</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0260323</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0260323</ELocationID><Abstract><AbstractText Label="OBJECTIVES">We previously reported the diagnostic and prognostic performance of neurofilament light chain (NfL), TAR DNA-binding protein 43 (TDP-43), and total tau (t-tau) in cerebrospinal fluid (CSF) and plasma as amyotrophic lateral sclerosis (ALS) biomarkers. The present study aimed to elucidate associations between clinical characteristics and the markers as well as mutual associations of the markers in ALS patients using the same dataset.</AbstractText><AbstractText Label="METHODS">NfL, TDP-43, and t-tau levels in CSF and plasma in 75 ALS patients were analyzed. The associations between those markers and clinical details were investigated by uni- and multivariate analyses. Correlations between the markers were analyzed univariately.</AbstractText><AbstractText Label="RESULTS">In multivariate analysis of CSF proteins, the disease progression rate (DPR) was positively correlated with NfL (&#x3b2;: 0.51, p = 0.007) and t-tau (&#x3b2;: 0.37, p = 0.03). Plasma NfL was correlated with age (&#x3b2;: 0.53, p = 0.005) and diagnostic grade (&#x3b2;: -0.42, p = 0.02) in multivariate analysis. Plasma TDP-43 was correlated negatively with split hand index (&#x3b2;: -0.48, p = 0.04) and positively with % vital capacity (&#x3b2;: 0.64, p = 0.03) in multivariate analysis. Regarding mutual biomarker analysis, a negative correlation between CSF-NfL and TDP-43 was identified (r: -0.36, p = 0.002).</AbstractText><AbstractText Label="CONCLUSIONS">Elevated NfL and t-tau levels in CSF may be biomarkers to predict rapid DPR from onset to sample collection. The negative relationship between CSF NfL and TDP-43 suggests that elevation of CSF TDP-43 in ALS is not a simple consequence of its release into CSF during neurodegeneration. The negative correlation between plasma TDP-43 and split hand index may support the pathophysiological association between plasma TDP-43 and ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kojima</LastName><ForeName>Yuta</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kasai</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-6424-0738</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noto</LastName><ForeName>Yu-Ichi</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmichi</LastName><ForeName>Takuma</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tatebe</LastName><ForeName>Harutsugu</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitaoji</LastName><ForeName>Takamasa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsuji</LastName><ForeName>Yukiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitani-Morii</LastName><ForeName>Fukiko</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-7959-4758</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shinomoto</LastName><ForeName>Makiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allsop</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Faculty of Health and Medicine, Division of Biomedical and Life Sciences, Lancaster University, Lancaster, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teramukai</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mizuno</LastName><ForeName>Toshiki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokuda</LastName><ForeName>Takahiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Functional Brain Imaging Research, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>11</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C054369">MAPT protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016900">Neurofilament Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C044882">neurofilament protein L</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016875">tau Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016900" MajorTopicYN="N">Neurofilament Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016875" MajorTopicYN="N">tau Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>11</Month><Day>29</Day><Hour>17</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34843548</ArticleId><ArticleId IdType="pmc">PMC8629269</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0260323</ArticleId><ArticleId IdType="pii">PONE-D-21-22395</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol 2011;7:639&#x2013;49. doi: 10.1038/nrneurol.2011.153</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.153</ArticleId><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al.. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018; 14:577&#x2013;89. doi: 10.1038/s41582-018-0058-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, De Schaepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S, et al.. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology 2017;88:2302&#x2013;9. doi: 10.1212/WNL.0000000000004029</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004029</ArticleId><ArticleId IdType="pubmed">28500227</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, et al.. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 2016;87:12&#x2013;20. doi: 10.1136/jnnp-2015-311387</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-311387</ArticleId><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, et al.. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease. JAMA neurology 2017;74:525&#x2013;32. doi: 10.1001/jamaneurol.2016.5398</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5398</ArticleId><ArticleId IdType="pmc">PMC5822207</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Henderson RD, David M, McCombe PA. Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0164625. doi: 10.1371/journal.pone.0164625</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0164625</ArticleId><ArticleId IdType="pmc">PMC5061412</ArticleId><ArticleId IdType="pubmed">27732645</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu LT, Bowser R. Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. Neurotherapeutics 2017;14:119&#x2013;34. doi: 10.1007/s13311-016-0503-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0503-x</ArticleId><ArticleId IdType="pmc">PMC5233638</ArticleId><ArticleId IdType="pubmed">27933485</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E, Kuiperij HB, van Blitterswijk MM, Veldink JH, Schelhaas HJ, van den Berg LH, et al.. TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012;13:446&#x2013;51. doi: 10.3109/17482968.2012.703208</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.703208</ArticleId><ArticleId IdType="pubmed">22873561</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilke C, Deuschle C, Rattay TW, Maetzler W, Synofzik M. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. Neurobiol Aging 2015;36:1072&#x2013;4. doi: 10.1016/j.neurobiolaging.2014.10.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2014.10.019</ArticleId><ArticleId IdType="pubmed">25453560</ArticleId></ArticleIdList></Reference><Reference><Citation>Grossman M, Elman L, McCluskey L, McMillan CT, Boller A, Powers J, et al.. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA neurology 2014;71:442&#x2013;8. doi: 10.1001/jamaneurol.2013.6064</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6064</ArticleId><ArticleId IdType="pmc">PMC3989393</ArticleId><ArticleId IdType="pubmed">24492862</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T, Kojima Y, Ohmichi T, Tatebe H, Tsuji Y, Noto YI, et al.. Combined use of CSF NfL and CSF TDP-43 improves diagnostic performance in ALS. Annals of clinical and translational neurology 2019;6:2489&#x2013;502. doi: 10.1002/acn3.50943</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.50943</ArticleId><ArticleId IdType="pmc">PMC6917342</ArticleId><ArticleId IdType="pubmed">31742901</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293&#x2013;9. doi: 10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al.. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13&#x2013;21. doi: 10.1016/s0022-510x(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0022-510x(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Kiernan MC. Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain 2006;129:2436&#x2013;46. doi: 10.1093/brain/awl172</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl172</ArticleId><ArticleId IdType="pubmed">16835248</ArticleId></ArticleIdList></Reference><Reference><Citation>De Jonghe B, Bastuji-Garin S, Durand MC, Malissin I, Rodrigues P, Cerf C, et al.. Respiratory weakness is associated with limb weakness and delayed weaning in critical illness. Crit Care Med 2007;35:2007&#x2013;15. doi: 10.1097/01.ccm.0000281450.01881.d8</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ccm.0000281450.01881.d8</ArticleId><ArticleId IdType="pubmed">17855814</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon NG, Turner MR, Vucic S, Al-Chalabi A, Shefner J, Lomen-Hoerth C, et al.. Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol 2014;76:643&#x2013;57. doi: 10.1002/ana.24273</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24273</ArticleId><ArticleId IdType="pmc">PMC4305209</ArticleId><ArticleId IdType="pubmed">25223628</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Kiernan MC, Yiannikas C, Stroud J, Vucic S. Split-hand index for the diagnosis of amyotrophic lateral sclerosis. Clin Neurophysiol 2013;124:410&#x2013;6. doi: 10.1016/j.clinph.2012.07.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2012.07.025</ArticleId><ArticleId IdType="pubmed">23017503</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiber H. Flow rate of cerebrospinal fluid (CSF)&#x2014;a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci 1994;122:189&#x2013;203. doi: 10.1016/0022-510x(94)90298-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510x(94)90298-4</ArticleId><ArticleId IdType="pubmed">8021703</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabrizi GM, Cavallaro T, Angiari C, Cabrini I, Taioli F, Malerba G, et al.. Charcot-Marie-Tooth disease type 2E, a disorder of the cytoskeleton. Brain 2007;130:394&#x2013;403. doi: 10.1093/brain/awl284</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awl284</ArticleId><ArticleId IdType="pubmed">17052987</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-Based Biomarker for ALS and FTLD. Mol Neurobiol 2018;55:7789&#x2013;801. doi: 10.1007/s12035-018-0947-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0947-6</ArticleId><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Schraen-Maschke S, Sergeant N, Dhaenens CM, Bombois S, Deramecourt V, Caillet-Boudin ML, et al.. Tau as a biomarker of neurodegenerative diseases. Biomark Med 2008;2:363&#x2013;84. doi: 10.2217/17520363.2.4.363</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/17520363.2.4.363</ArticleId><ArticleId IdType="pmc">PMC2993973</ArticleId><ArticleId IdType="pubmed">20477391</ArticleId></ArticleIdList></Reference><Reference><Citation>Tortelli R, Ruggieri M, Cortese R, D&#x2019;Errico E, Capozzo R, Leo A, et al.. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: a possible marker of disease severity and progression. Eur J Neurol 2012;19:1561&#x2013;7. doi: 10.1111/j.1468-1331.2012.03777.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2012.03777.x</ArticleId><ArticleId IdType="pubmed">22680408</ArticleId></ArticleIdList></Reference><Reference><Citation>Thouvenot E, Demattei C, Lehmann S, Maceski-Maleska A, Hirtz C, Juntas-Morales R, et al.. Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis. Eur J Neurol 2020;27:251&#x2013;7. doi: 10.1111/ene.14063</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14063</ArticleId><ArticleId IdType="pubmed">31437330</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, et al.. Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2019;90:157&#x2013;64. doi: 10.1136/jnnp-2018-318704</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Menke RA, Gray E, Lu CH, Kuhle J, Talbot K, Malaspina A, et al.. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Annals of clinical and translational neurology 2015;2:748&#x2013;55. doi: 10.1002/acn3.212</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.212</ArticleId><ArticleId IdType="pmc">PMC4531057</ArticleId><ArticleId IdType="pubmed">26273687</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber S, Spotorno N, Schreiber F, Acosta-Cabronero J, Kaufmann J, Machts J, et al.. Significance of CSF NfL and tau in ALS. J Neurol 2018; 265:2633&#x2013;45. doi: 10.1007/s00415-018-9043-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-9043-0</ArticleId><ArticleId IdType="pubmed">30187162</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra M, Paunesku T, Woloschak GE, Siddique T, Zhu LJ, Lin S, et al.. Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol 2007; 114:81&#x2013;94. doi: 10.1007/s00401-007-0240-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0240-7</ArticleId><ArticleId IdType="pubmed">17569064</ArticleId></ArticleIdList></Reference><Reference><Citation>Budini M, Buratti E. TDP-43 autoregulation: implications for disease. J Mol Neurosci 2011;45:473&#x2013;9. doi: 10.1007/s12031-011-9573-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9573-8</ArticleId><ArticleId IdType="pubmed">21681666</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, Geser F, Plotkin JB, Clark CM, Kwong LK, Yuan W, et al.. Variations in the progranulin gene affect global gene expression in frontotemporal lobar degeneration. Hum Mol Genet 2008;17:1349&#x2013;62. doi: 10.1093/hmg/ddn023</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddn023</ArticleId><ArticleId IdType="pmc">PMC2900863</ArticleId><ArticleId IdType="pubmed">18223198</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiperij HB, Abdo WF, van Engelen BG, Schelhaas HJ, Verbeek MM. TDP-43 plasma levels do not differentiate sporadic inclusion body myositis from other inflammatory myopathies. Acta Neuropathol 2010;120:825&#x2013;6. doi: 10.1007/s00401-010-0769-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0769-8</ArticleId><ArticleId IdType="pubmed">21046407</ArticleId></ArticleIdList></Reference><Reference><Citation>Foulds P, McAuley E, Gibbons L, Davidson Y, Pickering-Brown SM, Neary D, et al.. TDP-43 protein in plasma may index TDP-43 brain pathology in Alzheimer&#x2019;s disease and frontotemporal lobar degeneration. Acta Neuropathol 2008;116:141&#x2013;6. doi: 10.1007/s00401-008-0389-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0389-8</ArticleId><ArticleId IdType="pmc">PMC2464623</ArticleId><ArticleId IdType="pubmed">18506455</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon P, Kiernan MC, Vucic S. ALS pathophysiology: insights from the split-hand phenomenon. Clin Neurophysiol 2014;125:186&#x2013;93. doi: 10.1016/j.clinph.2013.07.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2013.07.022</ArticleId><ArticleId IdType="pubmed">24051071</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterberg H. Review: Tau in biofluids&#x2014;relation to pathology, imaging and clinical features. Neuropathol Appl Neurobiol 2017;43:194&#x2013;9. doi: 10.1111/nan.12378</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12378</ArticleId><ArticleId IdType="pubmed">28054371</ArticleId></ArticleIdList></Reference><Reference><Citation>Paladino P, Valentino F, Piccoli T, Piccoli F, La Bella V. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. Eur J Neurol 2009;16:257&#x2013;61. doi: 10.1111/j.1468-1331.2008.02405.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1468-1331.2008.02405.x</ArticleId><ArticleId IdType="pubmed">19138331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ros&#xe9;n C, Farahmand B, Skillb&#xe4;ck T, N&#xe4;gga K, Mattsson N, Kilander L, et al.. Benchmarking biomarker-based criteria for Alzheimer&#x2019;s disease: Data from the Swedish Dementia Registry, SveDem. Alzheimer&#x2019;s &amp; dementia: the journal of the Alzheimer&#x2019;s Association 2015;11:1470&#x2013;9. doi: 10.1016/j.jalz.2015.04.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2015.04.007</ArticleId><ArticleId IdType="pubmed">26079415</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarafino A, D&#x2019;Errico E, Introna A, Fraddosio A, Distaso E, Tempesta I, et al.. Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis. J Neurol 2018;265:2353&#x2013;62. doi: 10.1007/s00415-018-9008-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-018-9008-3</ArticleId><ArticleId IdType="pubmed">30116940</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Goossens J, Dedeene L, De Vocht J, Oldoni E, et al.. Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis. Neuropathol Appl Neurobiol 2019;45:291&#x2013;304. doi: 10.1111/nan.12511</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12511</ArticleId><ArticleId IdType="pubmed">29908069</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, et al.. Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 2018;90:e22&#x2013;e30. doi: 10.1212/WNL.0000000000004761</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000004761</ArticleId><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Pirpamer L, Hofer E, Voortman MM, Barro C, Leppert D, et al.. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nature communications 2020;11:812. doi: 10.1038/s41467-020-14612-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-14612-6</ArticleId><ArticleId IdType="pmc">PMC7010701</ArticleId><ArticleId IdType="pubmed">32041951</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>